U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H33NO4
Molecular Weight 459.5766
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRIFAROTENE

SMILES

CC(C)(C)C1=CC(=CC=C1N2CCCC2)C3=CC(=CC=C3OCCO)C4=CC=C(C=C4)C(O)=O

InChI

InChIKey=MFBCDACCJCDGBA-UHFFFAOYSA-N
InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)

HIDE SMILES / InChI

Description

Trifarotene is a novel first-in-class fourth-generation topical retinoid. It is a potent and selective RAR gamma-agonist. In multiple mouse models, trifarotene exhibited superior comedolytic, anti-inflammatory and depigmenting activity compared with other topical retinoids. In this 52-week study, trifarotene was safe, well-tolerated and effective in moderate facial and truncal acne. Trifarotene is in phase II clinical trial for the treatment of ichthyosis.

Originator

Approval Year

2019
334
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12 pg/mL
OTHER GOV
https://www.fda.gov/media/132145/download
200 mg 1 times / day steady-state, topical
dose: 200 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
TRIFAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
10.8 pg/mL
OTHER GOV
https://www.fda.gov/media/132145/download
200 mg 1 times / day steady-state, topical
dose: 200 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
TRIFAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
137 pg × h/mL
OTHER GOV
https://www.fda.gov/media/132145/download
200 mg 1 times / day steady-state, topical
dose: 200 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
TRIFAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
118 pg × h/mL
OTHER GOV
https://www.fda.gov/media/132145/download
200 mg 1 times / day steady-state, topical
dose: 200 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
TRIFAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
OTHER GOV
https://www.fda.gov/media/132145/download
200 mg 1 times / day steady-state, topical
dose: 200 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
TRIFAROTENE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.01 % 1 times / day multiple, topical
Studied dose
Dose: 0.01 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.01 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
unhealthy, 15 years (range: 12-17 years)
Health Status: unhealthy
Condition: acne vulgaris
Age Group: 15 years (range: 12-17 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
DLT: Skin irritation...
Other AEs: Skin exfoliation, Erythema...
Dose limiting toxicities:
Skin irritation (all grades, 8 patients)
Other AEs:
Skin exfoliation (all grades, 4 patients)
Erythema (all grades, 4 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
0.01 % 1 times / day multiple, topical
Studied dose
Dose: 0.01 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.01 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
unhealthy, 20 years (range: 18-34 years)
Health Status: unhealthy
Condition: acne vulgaris
Age Group: 20 years (range: 18-34 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
Other AEs: Skin irritation...
Other AEs:
Skin irritation (88.9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
0.01 % 1 times / day multiple, topical
Studied dose
Dose: 0.01 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.01 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
unhealthy, 20 years (range: 18-34 years)
n = 18
Health Status: unhealthy
Condition: acne vulgaris
Age Group: 20 years (range: 18-34 years)
Sex: M+F
Population Size: 18
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
Other AEs: Erythema...
Other AEs:
Erythema (88.9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Other AEs: Application site irritation, Application site pruritus...
Other AEs:
Application site irritation (7.5%)
Application site pruritus (2.4%)
Sunburn (2.6%)
Application site pain (< 1%)
Application site dryness (< 1%)
Application site discoloration (< 1%)
Application site rash (< 1%)
Application site swelling (< 1%)
Application site erosion (< 1%)
Erythema (< 1%)
Dermatitis allergic (< 1%)
Skin erythema (grade 1, 30.6%)
Scale (grade 1, 37.5%)
Dry skin face (grade 1, 39%)
Stinging skin (grade 1, 35.6%)
Skin erythema (grade 2, 28.4%)
Scale (grade 2, 27.1%)
Dry skin face (grade 2, 29.7%)
Stinging skin (grade 2, 20.6%)
Skin erythema (grade 3, 6.2%)
Scale (grade 3, 4.9%)
Dry skin face (grade 3, 4.8%)
Stinging skin (grade 3, 5.9%)
Skin erythema (grade 1, 26.5%)
Skin scarring (grade 1, 29.7%)
Dry skin (grade 1, 32.9%)
Stinging skin (grade 1, 26.1%)
Skin erythema (grade 2, 18.9%)
Skin scarring (grade 2, 13.7%)
Dry skin (grade 2, 16.1%)
Stinging skin (grade 2, 10.9%)
Skin erythema (grade 3, 5.2%)
Skin scarring (grade 3, 1.7%)
Dry skin (grade 3, 1.8%)
Stinging skin (grade 3, 4.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Disc. AE: Application site irritation, Application site erosion...
AEs leading to
discontinuation/dose reduction:
Application site irritation (1.1%)
Application site erosion (0.1%)
Application site pain (0.1%)
Acne (0.2%)
Skin irritation (0.2%)
Dermatitis allergic (0.1%)
Bronchitis (0.1%)
Muscle rupture (0.1%)
Tibia fracture (0.1%)
Major depression (0.1%)
Suicide attempt (0.1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
0.02 % 2 times / week multiple, topical
Highest studied dose
Dose: 0.02 %, 2 times / week
Route: topical
Route: multiple
Dose: 0.02 %, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/31713811/
unhealthy, adolescents; adults
Health Status: unhealthy
Condition: Lamellar Ichthyosis
Age Group: adolescents; adults
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/31713811/
Sources:
https://pubmed.ncbi.nlm.nih.gov/31713811/
12 g 2 times / week multiple, topical
Highest studied dose
Dose: 12 g, 2 times / week
Route: topical
Route: multiple
Dose: 12 g, 2 times / week
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
AEs

AEs

AESignificanceDosePopulation
Erythema all grades, 4 patients
0.01 % 1 times / day multiple, topical
Studied dose
Dose: 0.01 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.01 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
unhealthy, 15 years (range: 12-17 years)
Health Status: unhealthy
Condition: acne vulgaris
Age Group: 15 years (range: 12-17 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
Skin exfoliation all grades, 4 patients
0.01 % 1 times / day multiple, topical
Studied dose
Dose: 0.01 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.01 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
unhealthy, 15 years (range: 12-17 years)
Health Status: unhealthy
Condition: acne vulgaris
Age Group: 15 years (range: 12-17 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
Skin irritation all grades, 8 patients
DLT
0.01 % 1 times / day multiple, topical
Studied dose
Dose: 0.01 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.01 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
unhealthy, 15 years (range: 12-17 years)
Health Status: unhealthy
Condition: acne vulgaris
Age Group: 15 years (range: 12-17 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
Skin irritation 88.9%
0.01 % 1 times / day multiple, topical
Studied dose
Dose: 0.01 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.01 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
unhealthy, 20 years (range: 18-34 years)
Health Status: unhealthy
Condition: acne vulgaris
Age Group: 20 years (range: 18-34 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
Erythema 88.9%
0.01 % 1 times / day multiple, topical
Studied dose
Dose: 0.01 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.01 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
unhealthy, 20 years (range: 18-34 years)
n = 18
Health Status: unhealthy
Condition: acne vulgaris
Age Group: 20 years (range: 18-34 years)
Sex: M+F
Population Size: 18
Sources:
https://pubmed.ncbi.nlm.nih.gov/32017149
Application site pruritus 2.4%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Sunburn 2.6%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Application site irritation 7.5%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Application site discoloration < 1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Application site dryness < 1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Application site erosion < 1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Application site pain < 1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Application site rash < 1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Application site swelling < 1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Dermatitis allergic < 1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Erythema < 1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Stinging skin grade 1, 26.1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Skin erythema grade 1, 26.5%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Skin scarring grade 1, 29.7%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Skin erythema grade 1, 30.6%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Dry skin grade 1, 32.9%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Stinging skin grade 1, 35.6%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Scale grade 1, 37.5%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Dry skin face grade 1, 39%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Stinging skin grade 2, 10.9%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Skin scarring grade 2, 13.7%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Dry skin grade 2, 16.1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Skin erythema grade 2, 18.9%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Stinging skin grade 2, 20.6%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Scale grade 2, 27.1%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Skin erythema grade 2, 28.4%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Dry skin face grade 2, 29.7%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Skin scarring grade 3, 1.7%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Dry skin grade 3, 1.8%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Stinging skin grade 3, 4.3%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Dry skin face grade 3, 4.8%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Scale grade 3, 4.9%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Skin erythema grade 3, 5.2%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Stinging skin grade 3, 5.9%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Skin erythema grade 3, 6.2%
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf
Application site erosion 0.1%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Application site pain 0.1%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Bronchitis 0.1%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Dermatitis allergic 0.1%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Major depression 0.1%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Muscle rupture 0.1%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Suicide attempt 0.1%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Tibia fracture 0.1%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Acne 0.2%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Skin irritation 0.2%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Application site irritation 1.1%
Disc. AE
2 g 1 times / day multiple, topical
Recommended
Dose: 2 g, 1 times / day
Route: topical
Route: multiple
Dose: 2 g, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
unhealthy, >= 9 years
n = 1220
Health Status: unhealthy
Condition: acne vulgaris
Age Group: >= 9 years
Sex: M+F
Population Size: 1220
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587

inducer
781
substrate
1037

inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C8
911

CYP1A2
1524

CYP2B6
810

CYP2C19
1478

OAT
4

BCRP
699

P-gp
1461

BSEP
402

MRP
7
CYP2C8
693

CYP2B6
664

P-gp
1537

BCRP
561

OATP1B1/3
11

BSEP
52

MRP2
205

UGT
192
CYP1A2
701

CYP2B6
547
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BSEP
403
 no
CYP1A2
1692
 no
CYP1A2
1692
 no
CYP2B6
1001
 no
CYP2B6
1001
 no
CYP2C19
1553
 no
CYP2D6
1891
 no
CYP3A4
1925
 no
CYP3A4
1925
 no
MRP
7
 no
OAT
4
 no
P-gp
1650
 no
BCRP
773
 yes [IC50 2.78 uM]
unlikely
Comment: approximately 140,000-fold higher than the Cmax of trifarotene (9.6 pg/mL equivalent to 0.00002µM)
Page: 171.0
CYP2C9
1819
 yes [IC50 3.9 uM]
unlikely
Comment: approximately 140,000-fold higher than the Cmax of trifarotene (9.6 pg/mL equivalent to 0.00002µM)
Page: 171.0
CYP2C8
965
 yes [IC50 7.8 uM]
unlikely
Comment: approximately 300,000-fold higher than the Cmax of trifarotene (9.6 pg/mL equivalent to 0.00002µM)
Page: 171.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1037
 major
unlikely
Comment: The PBPK modeling predicted that Cmax and AUC of trifarotene could increase by 2.3- and 2.9-fold, respectively, if co-administered with strong CYP2C9 and CYP3A4 inhibitor. The simulated highest Cmax of trifarotene was markedly lower than the safety margin of trifarotene cream 50 µg/g.
Page: 59.0
CYP2B6
664
 minor
CYP2C8
693
 minor
UGT
192
 minor
CYP3A4
1737
 minor
unlikely
Comment: The PBPK modeling predicted that Cmax and AUC of trifarotene could increase by 2.3- and 2.9-fold, respectively, if co-administered with strong CYP2C9 and CYP3A4 inhibitor. The simulated highest Cmax of trifarotene was markedly lower than the safety margin of trifarotene cream 50 µg/g.
Page: 59.0
BSEP
52
 no
MRP2
205
 no
OATP1B1/3
11
 no
P-gp
1537
 no
BCRP
561
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
Ambeed
A298564
https://www.ambeed.com/products/895542-09-3.html
BLD Pharm
BD00769386
http://www.bldpharm.com/products/895542-09-3.html
BOC Sciences
895542-09-3
https://www.bocsci.com/product/trifarotene-cas-895542-09-3-343568.html
BioChemPartner
BCP31392
http://www.biochempartner.com/895542-09-3-BCP31392
CSNpharm
CSN21330
https://www.csnpharm.com/products/trifarotene.html
Chem Scene
CS-0018407
http://www.chemscene.com/895542-09-3.html
Chemspace
CSSB00134614707
https://chem-space.com/CSSB00134614707
Excenen
EX-A2704
https://www.excenen.com/searchresultlist.php?id=895542-09-3
MedChem Express
HY-100256
https://www.medchemexpress.com/Trifarotene.html
Smolecule
S545843
http://www.smolecule.com/products/s545843
THE BioTek
bt-286834
https://www.thebiotek.com/product/inhibitors/bt-286834
eNovation Chemicals
D674183
https://www.enovationchem.com/ProductDetails.asp?ProductID=D674183
PubMed

PubMed

TitleDatePubMed
Retinoids in Acne Management: Review of Current Understanding, Future Considerations, and Focus on Topical Treatments.
2018 Dec 1
Retinoids in Acne Management: Review of Current Understanding, Future Considerations, and Focus on Topical Treatments.
2018 Dec 1
Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne.
2019 Jun
Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne.
2020 Jan
Patents

Patents

20080015246
1
20100292296
1
Name Type Language
TRIFAROTENE
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
TRIFAROTENE [ORANGE BOOK]
Common Name English
CD-5789
Code English
(1,1':3',1''-TERPHENYL)-4-CARBOXYLIC ACID, 3''-(1,1-DIMETHYLETHYL)-4'-(2-HYDROXYETHOXY)-4''-(1-PYRROLIDINYL)-
Systematic Name English
Trifarotene [WHO-DD]
Common Name English
CD5789
Code English
TRIFAROTENE [MI]
Common Name English
trifarotene [INN]
Common Name English
TRIFAROTENE [USAN]
Common Name English
3''-TERT-BUTYL-4'-(2-HYDROXYETHOXY)-4''-(PYRROLIDIN-1-YL)(1,1':3',1'')TERPHENYL-4-CARBOXYLIC ACID
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 431014
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
WHO-ATC D10AD06
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
Code System Code Type Description
CAS
895542-09-3
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
NCI_THESAURUS
C118577
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
FDA UNII
0J8RN2W0HK
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
MERCK INDEX
m12163
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
INN
9582
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
DRUG CENTRAL
5350
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
SMS_ID
100000170499
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
ChEMBL
CHEMBL3707313
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID30237781
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
EVMPD
SUB184480
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
PUBCHEM
11518241
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
DAILYMED
0J8RN2W0HK
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
RXCUI
2205637
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
USAN
DE-16
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
DRUG BANK
DB12808
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
WIKIPEDIA
Trifarotene
Created by admin on Sat Dec 16 01:45:45 GMT 2023 , Edited by admin on Sat Dec 16 01:45:45 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of TRIFAROTENE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966